Prime Therapeutics, a pharmacy benefit manager owned by several Blue Cross and Blue Shield health insurers, promoted Mostafa Kamal to succeed the retiring Ken Paulus as chief executive officer.
The new leadership at Prime comes following the PBM’s $1.35 billion acquisition of MagellanRx Management, which was formerly part of Magellan Health, and divested in December by Centene. The acquisition is designed to unite Prime’s PBM capabilities with MagellanRx’s specialty drug management expertise, executives have said.
Prime is owned by 19 Blue Cross and Blue Shield Plans and manages the pharmacy benefits of nearly 38 million health plan members across the U.S. Prime’s board indicated Kamal is the right executive to grow the larger company.
“Mostafa’s vision for what we can become is inspiring and bold,” said Maurice Smith, Prime’s board chairman who is also president and CEO of one Prime’s major owners, Health Care Service Corporation, the parent of five Blue Cross and Blue Shield plans. “As Prime seeks to reimagine pharmacy benefit management, he is the right person to build on the strong foundation Ken leaves as he retires.”
Prime said Kamal, who has been president of Prime Therapeutics, and the CEO of Magellan Rx, played a “key role in shaping the 2022 agreement that brought together Prime and Magellan Rx.”
“Today, the united enterprise is ushering in the next generation of pharmacy solutions that promote the health and wellbeing of members and patients while improving affordability, access and quality,” Prime said in a statement.
Centene, which sells government subsidized health insurance including Medicaid, Medicare Advantage and individual coverage known as Obamacare, decided to exit the PBM space under chief executive officer Sarah London as part of her strategic plan to focus on core businesses.
Read the full article here
